Spots Global Cancer Trial Database for MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Official Title: Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Study ID: NCT04555551
Conditions
Interventions
Study Description
Brief Summary: This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment. The study treatment could stop the growth of the cancer, but it could also cause side effects.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York, United States
Contact Details
Name: Sham Mailankody, MBBS
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
